Global Ocular Genetic Diagnostics Market

Ocular Genetic Diagnostics Comprehensive Study by Test Methodologies (Next-generation Sequencing (NGS), Multiplex Ligation-Dependent Probe Amplification (MLPA), Fragment Analysis PCR for Repeat Expansion Analysis), Test Sample (Blood, Extracted DNA Samples), Gene Panel Tests (Corneal Dystrophy Gene Panel, Cataract Gene Panel (Congenital/Developmental), Bardet-Biedl Syndrome Gene Panel, Choroideremia - CHM gene - Deletion/Duplication, Congenital Stationary Night Blindness Gene Panel, Microphthalmia and Anophthalmia Gene Panel, Optic Atrophy Gene Panel, Leber Congenital Amaurosis Gene Panel, RB1 Gene Deletion/Duplication Analysis, RB1 Gene Analysis, Retinal Degeneration Gene Panel, Usher Syndrome Gene Panel, Usher Syndrome (USH2A) Deletion/Duplication Analysis), End User (Hospitals, Diagnostic Laboratories, Academic & Research Centers, Others) Players and Region - Global Market Outlook to 2026

Ocular Genetic Diagnostics Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Ocular Genetic Diagnostics Market Overview:
Increased adoption rates among healthcare professionals for early diagnosis of various hereditary and chronic disorders affecting the population, as well as increased awareness of the efficacy of molecular genetic testing for various hereditary and chronic disorders affecting the population, is expected to favor the growth of the Ocular Genetic Diagnostics field in the coming years. The need for ocular genetic diagnostics is expected to rise in the predicted period due to the rising prevalence of ocular genetic disorders.

Growth Drivers
  • Rising Awareness Regarding the Efficiency of Molecular Genetic Testing For Various Hereditary and Chronic Disorders

Roadblocks
  • Need of High Capital Investment

Opportunities
  • The Constant Development of New Treatment Guidelines and Improving Diagnostic Framework in Various Parts of the World
  • Increased Adoption Rates amongst Healthcare Professionals for Early Diagnosis

Challenges
  • Lack of Skilled and Experienced Personnel


Competitive Landscape:
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Blueprint Genetics (Finland), Columbia ophthalmology (United States), Centogene (Germany), Quest Diagnostics (United States), Medgenome (United States), Sankara Nethralaya (India), Fulgent Genetics (United States), GeneDx (United States), Devyser (Sweden) and Invitae Corporation (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Ocular Genetic Diagnostics market by 2026. Considering Market by Test Methodologies, the sub-segment i.e. Next-generation Sequencing (NGS) will boost the Ocular Genetic Diagnostics market. Considering Market by Test Sample, the sub-segment i.e. Blood will boost the Ocular Genetic Diagnostics market. Considering Market by Gene Panel Tests, the sub-segment i.e. Corneal Dystrophy Gene Panel will boost the Ocular Genetic Diagnostics market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Ocular Genetic Diagnostics market.

Latest Market Insights:
On October 22, 2021, MedGenome, based out of US and India, currently offers more than 550 genetic tests across key disease areas at its lab in Bangalore.

On June 02, 2021, Avellino Lab USA, Inc. (Avellino) announced full nationwide availability in the U.S. of AvaGen™, The Genetic Eye Test, as the first genetic test that helps determine a patient’s risk of keratoconus and the presence of other corneal dystrophies. The test allows for more confident management and treatment for patients with these conditions in order to protect and preserve patient vision.

What Can be Explored with the Ocular Genetic Diagnostics Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Ocular Genetic Diagnostics Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Ocular Genetic Diagnostics
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Ocular Genetic Diagnostics market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Ocular Genetic Diagnostics market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts And Strategic Business Planners, Ocular Genetic Diagnostics Testing Provider, Venture Capitalists And Private Equity Firms, Government Regulatory And Research Organizations and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Test Methodologies
  • Next-generation Sequencing (NGS)
  • Multiplex Ligation-Dependent Probe Amplification (MLPA)
  • Fragment Analysis PCR for Repeat Expansion Analysis

By Test Sample
  • Blood
  • Extracted DNA Samples

By Gene Panel Tests
  • Corneal Dystrophy Gene Panel
  • Cataract Gene Panel (Congenital/Developmental)
  • Bardet-Biedl Syndrome Gene Panel
  • Choroideremia - CHM gene - Deletion/Duplication
  • Congenital Stationary Night Blindness Gene Panel
  • Microphthalmia and Anophthalmia Gene Panel
  • Optic Atrophy Gene Panel
  • Leber Congenital Amaurosis Gene Panel
  • RB1 Gene Deletion/Duplication Analysis
  • RB1 Gene Analysis
  • Retinal Degeneration Gene Panel
  • Usher Syndrome Gene Panel
  • Usher Syndrome (USH2A) Deletion/Duplication Analysis

By End User
  • Hospitals
  • Diagnostic Laboratories
  • Academic & Research Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Awareness Regarding the Efficiency of Molecular Genetic Testing For Various Hereditary and Chronic Disorders
    • 3.3. Market Challenges
      • 3.3.1. Lack of Skilled and Experienced Personnel
    • 3.4. Market Trends
      • 3.4.1. Favorable Government Policies and Preemptive Steps are taken to Increase the Scope of Screening amongst the Population
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Ocular Genetic Diagnostics, by Test Methodologies, Test Sample, Gene Panel Tests, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Ocular Genetic Diagnostics (Value)
      • 5.2.1. Global Ocular Genetic Diagnostics by: Test Methodologies (Value)
        • 5.2.1.1. Next-generation Sequencing (NGS)
        • 5.2.1.2. Multiplex Ligation-Dependent Probe Amplification (MLPA)
        • 5.2.1.3. Fragment Analysis PCR for Repeat Expansion Analysis
      • 5.2.2. Global Ocular Genetic Diagnostics by: Test Sample (Value)
        • 5.2.2.1. Blood
        • 5.2.2.2. Extracted DNA Samples
      • 5.2.3. Global Ocular Genetic Diagnostics by: Gene Panel Tests (Value)
        • 5.2.3.1. Corneal Dystrophy Gene Panel
        • 5.2.3.2. Cataract Gene Panel (Congenital/Developmental)
        • 5.2.3.3. Bardet-Biedl Syndrome Gene Panel
        • 5.2.3.4. Choroideremia - CHM gene - Deletion/Duplication
        • 5.2.3.5. Congenital Stationary Night Blindness Gene Panel
        • 5.2.3.6. Microphthalmia and Anophthalmia Gene Panel
        • 5.2.3.7. Optic Atrophy Gene Panel
        • 5.2.3.8. Leber Congenital Amaurosis Gene Panel
        • 5.2.3.9. RB1 Gene Deletion/Duplication Analysis
        • 5.2.3.10. RB1 Gene Analysis
        • 5.2.3.11. Retinal Degeneration Gene Panel
        • 5.2.3.12. Usher Syndrome Gene Panel
        • 5.2.3.13. Usher Syndrome (USH2A) Deletion/Duplication Analysis
      • 5.2.4. Global Ocular Genetic Diagnostics by: End User (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Diagnostic Laboratories
        • 5.2.4.3. Academic & Research Centers
        • 5.2.4.4. Others
      • 5.2.5. Global Ocular Genetic Diagnostics Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Australia
          • 5.2.5.2.6. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Ocular Genetic Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Blueprint Genetics (Finland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Columbia ophthalmology (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Centogene (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Quest Diagnostics (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Medgenome (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sankara Nethralaya (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Fulgent Genetics (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GeneDx (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Devyser (Sweden)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Invitae Corporation (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Ocular Genetic Diagnostics Sale, by Test Methodologies, Test Sample, Gene Panel Tests, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Ocular Genetic Diagnostics (Value)
      • 7.2.1. Global Ocular Genetic Diagnostics by: Test Methodologies (Value)
        • 7.2.1.1. Next-generation Sequencing (NGS)
        • 7.2.1.2. Multiplex Ligation-Dependent Probe Amplification (MLPA)
        • 7.2.1.3. Fragment Analysis PCR for Repeat Expansion Analysis
      • 7.2.2. Global Ocular Genetic Diagnostics by: Test Sample (Value)
        • 7.2.2.1. Blood
        • 7.2.2.2. Extracted DNA Samples
      • 7.2.3. Global Ocular Genetic Diagnostics by: Gene Panel Tests (Value)
        • 7.2.3.1. Corneal Dystrophy Gene Panel
        • 7.2.3.2. Cataract Gene Panel (Congenital/Developmental)
        • 7.2.3.3. Bardet-Biedl Syndrome Gene Panel
        • 7.2.3.4. Choroideremia - CHM gene - Deletion/Duplication
        • 7.2.3.5. Congenital Stationary Night Blindness Gene Panel
        • 7.2.3.6. Microphthalmia and Anophthalmia Gene Panel
        • 7.2.3.7. Optic Atrophy Gene Panel
        • 7.2.3.8. Leber Congenital Amaurosis Gene Panel
        • 7.2.3.9. RB1 Gene Deletion/Duplication Analysis
        • 7.2.3.10. RB1 Gene Analysis
        • 7.2.3.11. Retinal Degeneration Gene Panel
        • 7.2.3.12. Usher Syndrome Gene Panel
        • 7.2.3.13. Usher Syndrome (USH2A) Deletion/Duplication Analysis
      • 7.2.4. Global Ocular Genetic Diagnostics by: End User (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Diagnostic Laboratories
        • 7.2.4.3. Academic & Research Centers
        • 7.2.4.4. Others
      • 7.2.5. Global Ocular Genetic Diagnostics Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Australia
          • 7.2.5.2.6. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Ocular Genetic Diagnostics: by Test Methodologies(USD Million)
  • Table 2. Ocular Genetic Diagnostics Next-generation Sequencing (NGS) , by Region USD Million (2015-2020)
  • Table 3. Ocular Genetic Diagnostics Multiplex Ligation-Dependent Probe Amplification (MLPA) , by Region USD Million (2015-2020)
  • Table 4. Ocular Genetic Diagnostics Fragment Analysis PCR for Repeat Expansion Analysis , by Region USD Million (2015-2020)
  • Table 5. Ocular Genetic Diagnostics: by Test Sample(USD Million)
  • Table 6. Ocular Genetic Diagnostics Blood , by Region USD Million (2015-2020)
  • Table 7. Ocular Genetic Diagnostics Extracted DNA Samples , by Region USD Million (2015-2020)
  • Table 8. Ocular Genetic Diagnostics: by Gene Panel Tests(USD Million)
  • Table 9. Ocular Genetic Diagnostics Corneal Dystrophy Gene Panel , by Region USD Million (2015-2020)
  • Table 10. Ocular Genetic Diagnostics Cataract Gene Panel (Congenital/Developmental) , by Region USD Million (2015-2020)
  • Table 11. Ocular Genetic Diagnostics Bardet-Biedl Syndrome Gene Panel , by Region USD Million (2015-2020)
  • Table 12. Ocular Genetic Diagnostics Choroideremia - CHM gene - Deletion/Duplication , by Region USD Million (2015-2020)
  • Table 13. Ocular Genetic Diagnostics Congenital Stationary Night Blindness Gene Panel , by Region USD Million (2015-2020)
  • Table 14. Ocular Genetic Diagnostics Microphthalmia and Anophthalmia Gene Panel , by Region USD Million (2015-2020)
  • Table 15. Ocular Genetic Diagnostics Optic Atrophy Gene Panel , by Region USD Million (2015-2020)
  • Table 16. Ocular Genetic Diagnostics Leber Congenital Amaurosis Gene Panel , by Region USD Million (2015-2020)
  • Table 17. Ocular Genetic Diagnostics RB1 Gene Deletion/Duplication Analysis , by Region USD Million (2015-2020)
  • Table 18. Ocular Genetic Diagnostics RB1 Gene Analysis , by Region USD Million (2015-2020)
  • Table 19. Ocular Genetic Diagnostics Retinal Degeneration Gene Panel , by Region USD Million (2015-2020)
  • Table 20. Ocular Genetic Diagnostics Usher Syndrome Gene Panel , by Region USD Million (2015-2020)
  • Table 21. Ocular Genetic Diagnostics Usher Syndrome (USH2A) Deletion/Duplication Analysis , by Region USD Million (2015-2020)
  • Table 22. Ocular Genetic Diagnostics: by End User(USD Million)
  • Table 23. Ocular Genetic Diagnostics Hospitals , by Region USD Million (2015-2020)
  • Table 24. Ocular Genetic Diagnostics Diagnostic Laboratories , by Region USD Million (2015-2020)
  • Table 25. Ocular Genetic Diagnostics Academic & Research Centers , by Region USD Million (2015-2020)
  • Table 26. Ocular Genetic Diagnostics Others , by Region USD Million (2015-2020)
  • Table 27. South America Ocular Genetic Diagnostics, by Country USD Million (2015-2020)
  • Table 28. South America Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 29. South America Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 30. South America Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 31. South America Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 32. Brazil Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 33. Brazil Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 34. Brazil Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 35. Brazil Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 36. Argentina Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 37. Argentina Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 38. Argentina Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 39. Argentina Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 40. Rest of South America Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 41. Rest of South America Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 42. Rest of South America Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 43. Rest of South America Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 44. Asia Pacific Ocular Genetic Diagnostics, by Country USD Million (2015-2020)
  • Table 45. Asia Pacific Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 46. Asia Pacific Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 47. Asia Pacific Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 48. Asia Pacific Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 49. China Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 50. China Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 51. China Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 52. China Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 53. Japan Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 54. Japan Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 55. Japan Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 56. Japan Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 57. India Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 58. India Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 59. India Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 60. India Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 61. South Korea Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 62. South Korea Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 63. South Korea Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 64. South Korea Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 65. Australia Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 66. Australia Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 67. Australia Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 68. Australia Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 72. Rest of Asia-Pacific Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 73. Europe Ocular Genetic Diagnostics, by Country USD Million (2015-2020)
  • Table 74. Europe Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 75. Europe Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 76. Europe Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 77. Europe Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 78. Germany Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 79. Germany Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 80. Germany Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 81. Germany Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 82. France Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 83. France Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 84. France Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 85. France Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 86. Italy Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 87. Italy Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 88. Italy Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 89. Italy Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 90. United Kingdom Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 91. United Kingdom Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 92. United Kingdom Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 93. United Kingdom Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 94. Netherlands Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 95. Netherlands Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 96. Netherlands Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 97. Netherlands Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 98. Rest of Europe Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 99. Rest of Europe Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 100. Rest of Europe Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 101. Rest of Europe Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 102. MEA Ocular Genetic Diagnostics, by Country USD Million (2015-2020)
  • Table 103. MEA Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 104. MEA Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 105. MEA Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 106. MEA Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 107. Middle East Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 108. Middle East Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 109. Middle East Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 110. Middle East Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 111. Africa Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 112. Africa Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 113. Africa Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 114. Africa Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 115. North America Ocular Genetic Diagnostics, by Country USD Million (2015-2020)
  • Table 116. North America Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 117. North America Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 118. North America Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 119. North America Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 120. United States Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 121. United States Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 122. United States Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 123. United States Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 124. Canada Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 125. Canada Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 126. Canada Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 127. Canada Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 128. Mexico Ocular Genetic Diagnostics, by Test Methodologies USD Million (2015-2020)
  • Table 129. Mexico Ocular Genetic Diagnostics, by Test Sample USD Million (2015-2020)
  • Table 130. Mexico Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2015-2020)
  • Table 131. Mexico Ocular Genetic Diagnostics, by End User USD Million (2015-2020)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Ocular Genetic Diagnostics: by Test Methodologies(USD Million)
  • Table 143. Ocular Genetic Diagnostics Next-generation Sequencing (NGS) , by Region USD Million (2021-2026)
  • Table 144. Ocular Genetic Diagnostics Multiplex Ligation-Dependent Probe Amplification (MLPA) , by Region USD Million (2021-2026)
  • Table 145. Ocular Genetic Diagnostics Fragment Analysis PCR for Repeat Expansion Analysis , by Region USD Million (2021-2026)
  • Table 146. Ocular Genetic Diagnostics: by Test Sample(USD Million)
  • Table 147. Ocular Genetic Diagnostics Blood , by Region USD Million (2021-2026)
  • Table 148. Ocular Genetic Diagnostics Extracted DNA Samples , by Region USD Million (2021-2026)
  • Table 149. Ocular Genetic Diagnostics: by Gene Panel Tests(USD Million)
  • Table 150. Ocular Genetic Diagnostics Corneal Dystrophy Gene Panel , by Region USD Million (2021-2026)
  • Table 151. Ocular Genetic Diagnostics Cataract Gene Panel (Congenital/Developmental) , by Region USD Million (2021-2026)
  • Table 152. Ocular Genetic Diagnostics Bardet-Biedl Syndrome Gene Panel , by Region USD Million (2021-2026)
  • Table 153. Ocular Genetic Diagnostics Choroideremia - CHM gene - Deletion/Duplication , by Region USD Million (2021-2026)
  • Table 154. Ocular Genetic Diagnostics Congenital Stationary Night Blindness Gene Panel , by Region USD Million (2021-2026)
  • Table 155. Ocular Genetic Diagnostics Microphthalmia and Anophthalmia Gene Panel , by Region USD Million (2021-2026)
  • Table 156. Ocular Genetic Diagnostics Optic Atrophy Gene Panel , by Region USD Million (2021-2026)
  • Table 157. Ocular Genetic Diagnostics Leber Congenital Amaurosis Gene Panel , by Region USD Million (2021-2026)
  • Table 158. Ocular Genetic Diagnostics RB1 Gene Deletion/Duplication Analysis , by Region USD Million (2021-2026)
  • Table 159. Ocular Genetic Diagnostics RB1 Gene Analysis , by Region USD Million (2021-2026)
  • Table 160. Ocular Genetic Diagnostics Retinal Degeneration Gene Panel , by Region USD Million (2021-2026)
  • Table 161. Ocular Genetic Diagnostics Usher Syndrome Gene Panel , by Region USD Million (2021-2026)
  • Table 162. Ocular Genetic Diagnostics Usher Syndrome (USH2A) Deletion/Duplication Analysis , by Region USD Million (2021-2026)
  • Table 163. Ocular Genetic Diagnostics: by End User(USD Million)
  • Table 164. Ocular Genetic Diagnostics Hospitals , by Region USD Million (2021-2026)
  • Table 165. Ocular Genetic Diagnostics Diagnostic Laboratories , by Region USD Million (2021-2026)
  • Table 166. Ocular Genetic Diagnostics Academic & Research Centers , by Region USD Million (2021-2026)
  • Table 167. Ocular Genetic Diagnostics Others , by Region USD Million (2021-2026)
  • Table 168. South America Ocular Genetic Diagnostics, by Country USD Million (2021-2026)
  • Table 169. South America Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 170. South America Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 171. South America Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 172. South America Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 173. Brazil Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 174. Brazil Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 175. Brazil Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 176. Brazil Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 177. Argentina Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 178. Argentina Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 179. Argentina Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 180. Argentina Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 181. Rest of South America Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 182. Rest of South America Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 183. Rest of South America Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 184. Rest of South America Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 185. Asia Pacific Ocular Genetic Diagnostics, by Country USD Million (2021-2026)
  • Table 186. Asia Pacific Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 187. Asia Pacific Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 188. Asia Pacific Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 189. Asia Pacific Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 190. China Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 191. China Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 192. China Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 193. China Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 194. Japan Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 195. Japan Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 196. Japan Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 197. Japan Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 198. India Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 199. India Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 200. India Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 201. India Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 202. South Korea Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 203. South Korea Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 204. South Korea Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 205. South Korea Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 206. Australia Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 207. Australia Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 208. Australia Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 209. Australia Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 210. Rest of Asia-Pacific Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 211. Rest of Asia-Pacific Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 212. Rest of Asia-Pacific Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 213. Rest of Asia-Pacific Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 214. Europe Ocular Genetic Diagnostics, by Country USD Million (2021-2026)
  • Table 215. Europe Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 216. Europe Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 217. Europe Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 218. Europe Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 219. Germany Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 220. Germany Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 221. Germany Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 222. Germany Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 223. France Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 224. France Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 225. France Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 226. France Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 227. Italy Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 228. Italy Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 229. Italy Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 230. Italy Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 231. United Kingdom Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 232. United Kingdom Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 233. United Kingdom Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 234. United Kingdom Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 235. Netherlands Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 236. Netherlands Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 237. Netherlands Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 238. Netherlands Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 239. Rest of Europe Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 240. Rest of Europe Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 241. Rest of Europe Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 242. Rest of Europe Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 243. MEA Ocular Genetic Diagnostics, by Country USD Million (2021-2026)
  • Table 244. MEA Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 245. MEA Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 246. MEA Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 247. MEA Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 248. Middle East Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 249. Middle East Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 250. Middle East Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 251. Middle East Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 252. Africa Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 253. Africa Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 254. Africa Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 255. Africa Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 256. North America Ocular Genetic Diagnostics, by Country USD Million (2021-2026)
  • Table 257. North America Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 258. North America Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 259. North America Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 260. North America Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 261. United States Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 262. United States Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 263. United States Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 264. United States Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 265. Canada Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 266. Canada Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 267. Canada Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 268. Canada Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 269. Mexico Ocular Genetic Diagnostics, by Test Methodologies USD Million (2021-2026)
  • Table 270. Mexico Ocular Genetic Diagnostics, by Test Sample USD Million (2021-2026)
  • Table 271. Mexico Ocular Genetic Diagnostics, by Gene Panel Tests USD Million (2021-2026)
  • Table 272. Mexico Ocular Genetic Diagnostics, by End User USD Million (2021-2026)
  • Table 273. Research Programs/Design for This Report
  • Table 274. Key Data Information from Secondary Sources
  • Table 275. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Ocular Genetic Diagnostics: by Test Methodologies USD Million (2015-2020)
  • Figure 5. Global Ocular Genetic Diagnostics: by Test Sample USD Million (2015-2020)
  • Figure 6. Global Ocular Genetic Diagnostics: by Gene Panel Tests USD Million (2015-2020)
  • Figure 7. Global Ocular Genetic Diagnostics: by End User USD Million (2015-2020)
  • Figure 8. South America Ocular Genetic Diagnostics Share (%), by Country
  • Figure 9. Asia Pacific Ocular Genetic Diagnostics Share (%), by Country
  • Figure 10. Europe Ocular Genetic Diagnostics Share (%), by Country
  • Figure 11. MEA Ocular Genetic Diagnostics Share (%), by Country
  • Figure 12. North America Ocular Genetic Diagnostics Share (%), by Country
  • Figure 13. Global Ocular Genetic Diagnostics share by Players 2020 (%)
  • Figure 14. Global Ocular Genetic Diagnostics share by Players (Top 3) 2020(%)
  • Figure 15. Global Ocular Genetic Diagnostics share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Blueprint Genetics (Finland) Revenue, Net Income and Gross profit
  • Figure 18. Blueprint Genetics (Finland) Revenue: by Geography 2020
  • Figure 19. Columbia ophthalmology (United States) Revenue, Net Income and Gross profit
  • Figure 20. Columbia ophthalmology (United States) Revenue: by Geography 2020
  • Figure 21. Centogene (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Centogene (Germany) Revenue: by Geography 2020
  • Figure 23. Quest Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 24. Quest Diagnostics (United States) Revenue: by Geography 2020
  • Figure 25. Medgenome (United States) Revenue, Net Income and Gross profit
  • Figure 26. Medgenome (United States) Revenue: by Geography 2020
  • Figure 27. Sankara Nethralaya (India) Revenue, Net Income and Gross profit
  • Figure 28. Sankara Nethralaya (India) Revenue: by Geography 2020
  • Figure 29. Fulgent Genetics (United States) Revenue, Net Income and Gross profit
  • Figure 30. Fulgent Genetics (United States) Revenue: by Geography 2020
  • Figure 31. GeneDx (United States) Revenue, Net Income and Gross profit
  • Figure 32. GeneDx (United States) Revenue: by Geography 2020
  • Figure 33. Devyser (Sweden) Revenue, Net Income and Gross profit
  • Figure 34. Devyser (Sweden) Revenue: by Geography 2020
  • Figure 35. Invitae Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 36. Invitae Corporation (United States) Revenue: by Geography 2020
  • Figure 37. Global Ocular Genetic Diagnostics: by Test Methodologies USD Million (2021-2026)
  • Figure 38. Global Ocular Genetic Diagnostics: by Test Sample USD Million (2021-2026)
  • Figure 39. Global Ocular Genetic Diagnostics: by Gene Panel Tests USD Million (2021-2026)
  • Figure 40. Global Ocular Genetic Diagnostics: by End User USD Million (2021-2026)
  • Figure 41. South America Ocular Genetic Diagnostics Share (%), by Country
  • Figure 42. Asia Pacific Ocular Genetic Diagnostics Share (%), by Country
  • Figure 43. Europe Ocular Genetic Diagnostics Share (%), by Country
  • Figure 44. MEA Ocular Genetic Diagnostics Share (%), by Country
  • Figure 45. North America Ocular Genetic Diagnostics Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Blueprint Genetics (Finland)
  • Columbia ophthalmology (United States)
  • Centogene (Germany)
  • Quest Diagnostics (United States)
  • Medgenome (United States)
  • Sankara Nethralaya (India)
  • Fulgent Genetics (United States)
  • GeneDx (United States)
  • Devyser (Sweden)
  • Invitae Corporation (United States)
Select User Access Type

Key Highlights of Report


Oct 2021 205 Pages 52 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Ocular Genetic Diagnostics Market Quantitative research analysis
Global Ocular Genetic Diagnostics Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Ocular Genetic Diagnostics market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Ocular Genetic Diagnostics market are Blueprint Genetics (Finland), Columbia ophthalmology (United States), Centogene (Germany), Quest Diagnostics (United States), Medgenome (United States), Sankara Nethralaya (India), Fulgent Genetics (United States), GeneDx (United States), Devyser (Sweden) and Invitae Corporation (United States), to name a few.
"Favorable Government Policies and Preemptive Steps are taken to Increase the Scope of Screening amongst the Population" is seen as one of major influencing trends for Ocular Genetic Diagnostics Market during projected period 2020-2026.

Know More About Global Ocular Genetic Diagnostics Market Report?

Have a Query? Click Here

Other Related Reports

Diabetes Associated Ophthalmic Treatment Comprehensive Study by Type (Drugs, Devices), Application (Children, Adults), Disease Type (Diabetic Retinopathy, Diabetic Macular Edema, Cataracts, Glaucoma)...
$ 3350
Pelvic Ring Fixation Comprehensive Study by Type (Type A, Type B, Type C), Indication (Pubic Symphysis Disruption, Sacroiliac Dislocation, Sacrum Fracture, Others), Type Of Fracture (Internal Pelvic...
$ 3750
Down syndrome Comprehensive Study by Type (Trisomy 21 (Nondisjunction), Mosaicism, Translocation), Disorder Severity (Mild Down Syndrome (IQ: 50–69), Moderate Down Syndrome (IQ: 35–50), Severe Down S...
$ 3650
Fibrosarcoma Treatment Comprehensive Study by Type (Infantile/Congenital-Type Fibrosarcoma, Adult-Type Fibrosarcoma), Technology (X-Ray, Computed Tomography (Ct), Magnetic Resonance Imaging (Mri), Bo...
$ 3750
Brain Hemorrhage Comprehensive Study by Drug (Anti-hypertensive Drugs, Anti-convulsants Drugs, Hyperosmostic Drugs, Others (others include Anti-epileptic Drugs, Anti-pyretic Drugs, etc.)), Distributi...
$ 3750
Acromegaly Gigantism Treatment Comprehensive Study by Type (Somatostatin analogs, GHRA), End Use (Hospitals, Clinics, Others) Players and Region - Global Market Outlook to 2028
$ 3500